Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Phase 2 Study Active, not recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Active, not recruiting
    • Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Cellectar Biosciences to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

Sep 3, 2015

Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics

Aug 21, 2015

Cellectar Biosciences Announces 2nd Quarter Financial Results

Aug 12, 2015

Cellectar Biosciences to Host Conference Call on August 12th to Discuss Second Quarter Financial Results and Provide Update on Development Plans

Aug 7, 2015

Cellectar Appoints Industry Veteran Jim Caruso President and Chief Executive Officer

Jun 16, 2015

Cellectar Biosciences Announces CLR1502 Development Program to be Classified as Combination Product by U.S. Food and Drug Administration

Jun 11, 2015

Cellectar Biosciences Announces Intent to Adjourn Annual Meeting Of Stockholders

May 26, 2015

Cellectar Biosciences Reports First Quarter 2015 Financial Results and Provides Update on Clinical Programs

May 21, 2015

Cellectar Biosciences to Host Conference Call on May 21st to Discuss First Quarter 2015 Results and Provide Update on Development Programs

May 20, 2015

Cellectar Biosciences Reschedules Release of First Quarter Financials and Quarterly Conference Call

May 11, 2015
RSS
    • 1...
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    • 36
    © 2025 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A